In the newest creative spin on the benefits of bev, the phase 3 AvaALL trial randomized patients with non-small cell lung cancer (NSCLC) who failed after first-line platinum chemo + bevacizumab to salvage physician’s choice chemo +/- more bev. Let’s look at what the extra bev bought: not the primary endpoint of overall survival nor even progression-free survival (PFS). But alas! If PFS doesn’t mean much, perhaps third progression (PFS3) is where it’s at. TBL: This Roche “funded, designed, conducted, collected, managed, analyzed, interpreted, prepared, reviewed, approved and submitted” pub reports that continuing bev after first progression of NSCLC is associated with a significant improvement in PFS3. So yeah. | Gridelli, JAMA Oncol 2018


Popular Posts